Patent Foramen Ovale
Key Points
Key Points
- For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
- For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.
Management
...nagement
...s Regarding Percutaneous PFO Closure...
...ng considered for PFO closure, clinicians should...
...atients being considered for PFO clos...
...n patients being considered for PFO closure,...
...tients being considered for PFO closure, cli...
...s being considered for PFO closure thought to b...
...ng considered for PFO closure, clinicia...
...g considered for PFO closure, clinici...
...being considered for PFO closure, clinicians may...
...ndergoing PFO closure, patients should be assess...
...gher risk alternative mechanism of...
...ng PFO closure, patients should be assesse...
...with a PFO detected after stroke and no...
...ts younger than 60 years with a PFO and an emb...
...nform patients that presence of a la...
...re may be offered in other populati...
PFO closure may be offered to younger patients...
...nt for whom PFO closure is being considere...
...mendations Regarding Medical The...
...atients who opt to receive medical th...
...n patients who would otherwise be considere...
...gure 1. Management Algorithm...